Neutralizing Power of Serum Antibodies - 2
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorCentre Hospitalier Régional d'Orléans
About this trial
Severe forms of COVID-19 and Monkeypox affect immunocompromised and comorbid individuals. Vaccination and monoclonal antibody therapies induce neutralizing antibodies. This neutralizing power is recognized as a correlate of protection against a new infection. This study aims to describe the neutralizing power of serum and nasal antibodies over time, in relation to SARS-CoV-2 and MPXV vaccines or treatments received.
Eligibility criteria
Qualifiers
Adults (≥18 years)
Patients receiving or scheduled to receive anti-SARS-CoV-2 and/or anti-MPXV vaccines or monoclonal antibodies
Patients have provided written informed consent
Disqualifiers
Persons under guardianship or curatorship
Persons under legal protection,
Persons persons deprived of liberty
Persons not affiliated to a social security scheme
Trial design
Treatments tested in this trial
- Sample collection (blood and optional nasal swab)
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov